George Golumbeski signs on at a European specialist VC firm with $265M to bet on genetic diseases
Since decamping from Celgene during a management overhaul close to three years ago, George Golumbeski has been channeling years of connections and dealmaking experience to a select group of company boards as a self-styled independent biotech exec — while dabbling in a somewhat behind-the-scenes role in venture capital at places like ARCH and Vertex Ventures.
He’s now adding one more gig to that menu, this time to scout promising startup ideas for genetic diseases.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.